Today: 23 April 2026
Diodes stock jumps 26% after Q4 update and fresh 2028 targets — what DIOD traders watch next
12 February 2026
1 min read

Diodes stock jumps 26% after Q4 update and fresh 2028 targets — what DIOD traders watch next

New York, February 11, 2026, 18:41 EST — Activity picked up after the close.

  • Shares of Diodes (DIOD) jumped roughly 26% after hours, briefly hitting $81.57.
  • The chipmaker posted fourth-quarter revenue of $391.6 million, a 15.4% increase from last year. Looking ahead, it expects first-quarter revenue around $395 million, give or take 3%.
  • The company’s management rolled out fresh 2028 goals: $2 billion in annual revenue, plus non-GAAP EPS north of $4.

Shares of Diodes Incorporated surged roughly 26% in after-hours trading Wednesday, sending the Nasdaq-listed chipmaker up to about $78 after it posted its quarterly results alongside an upbeat outlook.

The shift is key: smaller analog and power chip suppliers are working to show investors that demand is holding steady, not just rebounding. Diodes, with exposure to automotive, industrial, computing, and communications markets, faces quick changes in order visibility.

Management hammered that theme, pointing to stronger demand in multiple markets and forecasting “above-seasonal” revenue this quarter. In chip circles, talk like that tends to catch on—especially after a year stuffed with wary outlooks.

Diodes reported fourth-quarter revenue of $391.6 million, up from $339.3 million a year ago. GAAP net income landed at $10.2 million, translating to $0.22 per diluted share. Non-GAAP EPS, which excludes acquisition-related expenses and other items, came in at $0.34.

The company reported EBITDA of $41.9 million, representing 10.7% of revenue. Share repurchases totaled $23.8 million for the quarter.

Chief Executive Gary Yu is guiding Diodes to first-quarter revenue near $395 million, give or take 3%, and sees GAAP gross margin landing around 31.5%, with a margin for error of 1%. “That is significantly better than typical seasonality,” Yu said. Business Wire

Along with its results, the company rolled out a fresh set of three-year targets: $2 billion in yearly revenue, a gross margin hitting at least 35%, and non-GAAP EPS of $4.00 or above by 2028, per an investor presentation.

Even so, the road ahead isn’t smooth. Yu noted that Diodes is focused on boosting factory efficiency and trimming what he called “underloading costs”—the hit to margins that happens when plants aren’t running full tilt and fixed expenses end up divided among a smaller number of chips.

The company noted these numbers are unaudited and still preliminary, warning that figures might shift when it files its Form 10-K annual report covering the year that ended Dec. 31, 2025.

Traders head into Thursday focused on whether the stock can keep its momentum as analysts update their models after the fresh targets and margin comments. Looking ahead, U.S. markets will see a shortened week—Nasdaq and NYSE are set to be shut for Presidents Day on Feb. 16.

Stock Market Today

  • Altimmune Eyes 2026 Catalysts with Pemvidutide Trials and Funding Concerns
    April 23, 2026, 2:57 PM EDT. Altimmune (ALT) centers its 2026 outlook on pemvidutide, a dual receptor agonist targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder, and liver disease. Key catalysts include the phase II RECLAIM study top-line data on alcohol use disorder expected in Q3 2026 and the planned pivotal phase III start for MASH. Success in these trials could broaden pemvidutide's market potential and shift investor sentiment. Altimmune's distinctive "liver first" approach focuses on combining glucagon and GLP-1 pathways to reduce liver fat and inflammation while supporting weight loss, addressing a competitive space seeking durable liver benefits beyond weight reduction. Financing risks remain a key concern amid evolving clinical development. Investors watch closely as late-stage execution and trial outcomes will influence Altimmune's valuation and future positioning.

Latest article

ServiceNow stock tumbles despite Q1 beat and higher 2026 outlook

ServiceNow stock tumbles despite Q1 beat and higher 2026 outlook

23 April 2026
ServiceNow shares dropped 18.7% to $83.77 after reporting first-quarter results that beat estimates and raising its 2026 subscription revenue forecast. Investors focused on delayed Middle East government deals, which cut subscription growth by 0.75 percentage point, and concerns over AI’s impact on software demand.
IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

23 April 2026
IBM shares fell 9.6% to $227.72 after first-quarter results showed slowing software and consulting growth, despite beating earnings estimates. The selloff spread to ServiceNow, Microsoft, and Adobe, while chip stocks rose. IBM reported $15.92 billion in revenue, up 9%, and raised its quarterly dividend to $1.69. Investors reacted to concerns over AI’s impact on older software businesses.
Micron stock price jumps nearly 10% after CFO says HBM4 shipments have started
Previous Story

Micron stock price jumps nearly 10% after CFO says HBM4 shipments have started

Decent Holding (DXST) stock price jumps 80% on huge volume as lock-up ends, reverse split vote nears
Next Story

Decent Holding (DXST) stock price jumps 80% on huge volume as lock-up ends, reverse split vote nears

Go toTop